Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Neuren Pharmaceuticals (ASX:NEU) announced that results from its Phase 2 clinical trial of NNZ-2591 in children and adolescents with Phelan-McDermid syndrome have been published in Neurology Genetics
A French court hears charges against a hypnotherapist accused of drugging and sexually abusing multiple women.
UC San Diego Health has commenced clinical use of 4DMedical’s (ASX:4DX) advanced respiratory imaging technology, CT:VQ.
Solstice Minerals (ASX:SLS) has recommenced Phase 1 reverse circulation drilling at its 100%-owned Nanadie Copper-Gold Project.
Johnson & Johnson (NYSE:JNJ) announced on Tuesday, January 6, 2026, that its Phase 2b JASMINE study of nipocalimab in adults with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and key secondary endpoints.
Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).
This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.
Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.
The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.
Atossa Therapeutics (NASDAQ:ATOS) reached a significant regulatory milestone on January 6, 2026, receiving a "Study May Proceed" letter from the U.S. FDA for its Investigational New Drug (IND) application.
Aclarion (NASDAQ:ACON) reached a significant clinical milestone on Tuesday, January 6, 2026, announcing the first patient enrollments at two prestigious new sites: Northwestern Medicine and Scripps Health.
This expansion brings the total number of active enrollment sites to four, with seven leading U.S. spine centers having completed full regulatory and operational setup.
Radware (NASDAQ:RDWR) announced Tuesday, January 6, 2026, that it has doubled its global cloud security mitigation capacity, jumping from 15 Tbps to 30 Tbps.
The massive upgrade comes in response to a "seismic shift" in the threat landscape, headlined by an 85% surge in network DDoS attacks during the first half of 2025.
